Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

por Daud, Adil, Kluger, Harriet M, Kurzrock, Razelle, Schimmoller, Frauke, Weitzman, Aaron L, Samuel, Thomas A, Moussa, Ali H, Gordon, Michael S, Shapiro, Geoffrey I
Publicado 2017